(3E,5E,8S,9E,11S,12R,13E,15E,18S)-3-[[[6-Deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-β-D-mannopyranosyl]oxy]methyl]-12-[[6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-β-D-lyxo-hexopyranosyl]oxy]-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-oxacyclooctadeca-3,5,9,13,15-pentaen-2-one; Clostomicin B1; Dificid; Dificlir; Fidaxomicin; Fidaxomycin; Lipiarmicin; Lipiarmycin; Lipiarmycin A 3; OPT 80; PAR 01; PAR 101; R-Tiacumicin B; Tiacumicin B
CAS号:
873857-62-6
分子式:
C₅₂H₇₄Cl₂O₁₈
外观:
白色固体
熔点:
>160°C (dec.)
分子量:
1058.04
储存:
冰箱保存
溶解度:
DMSO (Slightly), Methanol (Slightly)
种类:
Standards; Chiral Molecules; Enzyme Activators and Inhibitors; Others; Pharmaceutical/API Drug Impurities/Metabolites; Antibotics;
应用:
Fidaxomicin is a nonabsorbed macrocyclic antibiotic, and is the first antimicrobial to be approved by the FDA for the treatment of Clostridium difficile infection (CDI) in 20 years. Fidaxomicin works by inhibiting sporulation by CDI, sustaining clinical response and reducing recurrences of this pathogen.
您的位置：
